what are the risks of compounded semaglutide Comparative safety and side effects and tirzepatide: Implications for clinical decision-making in obesity management Is Compounded Semaglutide Safe? Risks,

Mazidi M, Rezaie P, Gao HK, Kengne AP

No, GLP-1 receptor agonists are not FDA-approved for Alzheimer's disease prevention or treatment

Tirzepatide has a shorter half-life of approximately five days compared to semaglutide at seven days

Constipation can occur as gastric emptying slows significantly

10.1016/j.bbrc.2019.01.103 Summary Keywords heart failure, cognitive impairment, type 2 diabetes, glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter 2 inhibitors Citation Riemma MA, Mele E, Donniacuo M, Telesca M, Bellocchio G, Castaldo G, Rossi F, De Angelis A, Cappetta D, Urbanek K and Berrino L (2024) Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors, anti-diabetic drugs in heart failure and cognitive impairment: potential mechanisms of the protective effects